3,4-Dihydropyrazine 2,3-b pyrazin-2 (1H) -one compounds as mTOR kinase inhibitors for oncological indications and diseases associated with the mTOR / PI3K / Akt pathway

摘要

A compound having the formula (II): ** Formula ** or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, wherein: R1 is pyridyl substituted with one or more substituents independently selected from the group consisting of C1- alkyl 8 substituted or unsubstituted, substituted or unsubstituted heterocyclyl, halogen, aminocarbonyl, cyano, hydroxyalkyl, -OR and -NR2, where each R is independently H, or a substituted or unsubstituted C1-4 alkyl; R2 is substituted or unsubstituted cycloalkyl, and R3 is H, or a substituted or unsubstituted C1-8 alkyl; wherein the term "substituted" denotes a substitution with any of the substituents recited in the subsequent claims or with halogen; I rent; hydroxyl; alkoxy; alkoxyalkyl; Not me; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen ( = O); B (OH) 2, O (alkyl) aminocarbonyl; cocloalkyl, which may be monocyclic or polycyclic condensed or non-condensed; heterocyclyl; which can be monocyclic or polycyclic condensed or non-condensed; condensed or non-condensed monocyclic or polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy or heterocyclyl alkoxy.